MedTrace Logo

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2017-03-10

No results posted yet for this study

Summary

This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.

Conditions

  • Autistic Disorder

Interventions

DRUG

citalopram hydrobromide

10mg/5ml solution

OTHER

placebo

up to equivalent of 20 mg of active comparator daily

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Boston University

    lead OTHER

Principal Investigators

  • Bryan King, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-10-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086645 on ClinicalTrials.gov